Adding unique value to meet a major challenge of our time.
Diabetes is the fastest growing chronic disease.
From 100m people with diabetes in 1980 to 600m now — one in every ten adults — to 1.3b by 2050.
Diabetes is a key driver of soaring healthcare costs worldwide, causing USD 1tn of annual expenditure - an increase of over 300% in the last 15 years.
Rapid growth in technology to address huge unmet needs is driven by innovation across all areas of diabetes and related healthcare, resulting in multiple multi-billion dollar markets.
1.3bn
people living with diabetes by 2050
>300%
increase in healthcare costs in the last 15 years
$115bn
market for diabetes technology this decade
We’ve got just the right setup to tackle this.
The Diabetes Venture Fund taps into this extraordinary opportunity, bringing together a unique set of partners to invest with impact globally in exceptional diabetes technology startups.
Leveraging the knowhow and networks of Serpentine Ventures, the investment arm of Swiss Ventures Group, and the DCB, a global center for technology innovation in diabetes.
From proprietary deal flow and company building expertise, to networks of key opinion leaders and corporate partners, to research facilities and deep medtech knowledge - all dedicated to bringing world class products to market.